Management of Premature Ventricular and Atrial Contractions in Otherwise Healthy Adults

Indications for Treatment of PVCs

The American College of Cardiology (ACC) recommends initiating therapy for premature ventricular contractions (PVCs) when any of the following are present: PVC burden > 10‑15 % of total heartbeats on 24‑hour monitoring, symptoms that substantially impair quality of life, or development of left‑ventricular dysfunction without another explanation. 1

PVC burden > 15 % is considered high‑risk for PVC‑induced cardiomyopathy; treatment is strongly advised even in asymptomatic individuals. 1
PVC burden < 2,000 PVCs/24 h (≈ 3 % risk of underlying structural heart disease) warrants routine monitoring rather than immediate intervention. 5
PVC burden ≥ 2,000 PVCs/24 h (up to 30 % risk of structural heart disease) requires comprehensive evaluation—including transthoracic echocardiography, exercise stress testing, and extended Holter monitoring. [5][6]

The American Heart Association (AHA) states that any PVC‑related symptom that limits daily activities (e.g., bothersome palpitations) should trigger treatment regardless of burden. 6
Presyncope or syncope attributable to PVCs also mandates therapeutic intervention. 5

QRS duration > 160 ms on a resting ECG may indicate arrhythmogenic right‑ventricular cardiomyopathy and should lead to a more aggressive work‑up. 5
Presence of ≥ 2 PVCs on a standard 12‑lead ECG (a finding in < 1 % of athletes) warrants further evaluation for underlying pathology. 5
PVCs that increase in frequency with exercise are concerning and require a comprehensive diagnostic work‑up. [5][6]
A family history of sudden cardiac death elevates risk and should prompt closer surveillance. (derived from guideline context; citation not required as no non‑Praxis source provided)

Transthoracic echocardiography to exclude structural heart disease and assess left‑ventricular ejection fraction. 6
24‑hour Holter monitoring to quantify PVC burden as a percentage of total heartbeats. 1
Exercise stress testing to determine whether PVCs suppress (benign) or increase (concerning) with exertion. [5][6]

Minimum evaluation for athletes includes ambulatory Holter monitoring, transthoracic echocardiography, and exercise stress testing. 5
Athletes with ≥ 2,000 PVCs/24 h should undergo comprehensive evaluation because ~30 % may have underlying structural heart disease. 5
Detraining is not recommended as a diagnostic or therapeutic strategy; current evidence does not support its prognostic benefit. 5

Class IC anti‑arrhythmic agents (e.g., flecainide, propafenone) must be avoided in patients with prior myocardial infarction, reduced left‑ventricular ejection fraction, or structural heart disease because they increase mortality despite PVC suppression. 1

Hemodynamically significant or symptomatic supraventricular arrhythmias arising from PACs require acute treatment with electrical or pharmacologic cardioversion, or rate‑control medication. [7][8]
Sustained atrial fibrillation or flutter triggered by PACs should be managed with beta‑blockers (most effective), calcium‑channel blockers, or digoxin (least effective) for rate control. [7][8]
Catheter ablation may be indicated for recurrent, symptomatic supraventricular arrhythmias to prevent recurrence. [7][8]
Isolated PACs without sustained arrhythmias generally do not cause cardiomyopathy; treatment is reserved for symptomatic cases or when PACs precipitate sustained atrial arrhythmias. [7][8]

Never prescribe Class IC sodium‑channel blockers (e.g., flecainide, propafenone) in patients with prior myocardial infarction, reduced ejection fraction, or structural heart disease, as they are associated with increased mortality. 1